Long-term persistence of primary genotypic resistance after HIV-1 seroconversion

David Pao; Ushan Andrady; Janette Clarke; Gillian Dean; Susan Drake; Martin Fisher; Tanya Green; Siva Kumar; Maurice Murphy; Alan Tang; Stephen Taylor; David White; Gillian Underhill; Deenan Pillay; Patricia Cane

doi:10.1097/00126334-200412150-00006

Long-term persistence of primary genotypic resistance after HIV-1 seroconversion

David Pao, Ushan Andrady, Janette Clarke, Gillian Dean, Susan Drake, Martin Fisher, Tanya Green, Siva Kumar, Maurice Murphy, Alan Tang, Stephen Taylor, David White, Gillian Underhill, Deenan Pillay, Patricia Cane^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

106 Citations (Scopus)

Abstract

Primary infection with drug-resistant HIV-1 is well documented. We have followed up patients infected with such viruses to determine the stability of resistance-associated mutations. Fourteen patients who experienced primary infection with genotypic evidence of resistance were followed for up to 3 years. Drug resistance-associated mutations persisted over time in most patients studied. In particular, M41L, T69N, K103N, and T215 variants within reverse transcriptase (RT) and multidrug resistance demonstrated little reversion to wild-type virus. By contrast, Y181C and K219Q in RT, occurring alone, disappeared within 25 and 9 months, respectively. Multidrug resistance in 2 patients was found to be stable for up to 18 months, the maximum period studied. We conclude that certain resistance-associated mutations are highly stable and these data support the recommendation that all new HIV diagnoses in areas where primary resistance may occur should undergo genotyping irrespective of whether the date of seroconversion is known.

Original language	English
Pages (from-to)	1570-1573
Number of pages	4
Journal	Journal of Acquired Immune Deficiency Syndromes
Volume	37
Issue number	5
DOIs	https://doi.org/10.1097/00126334-200412150-00006
Publication status	Published - 15 Dec 2004

Keywords

HIV-1
Persistence of mutations
Primary drug resistance

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/00126334-200412150-00006

Cite this

Pao, D., Andrady, U., Clarke, J., Dean, G., Drake, S., Fisher, M., Green, T., Kumar, S., Murphy, M., Tang, A., Taylor, S., White, D., Underhill, G., Pillay, D., & Cane, P. (2004). Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. Journal of Acquired Immune Deficiency Syndromes, 37(5), 1570-1573. https://doi.org/10.1097/00126334-200412150-00006

@article{4c381ba1ee20409abf097fab5e947125,

title = "Long-term persistence of primary genotypic resistance after HIV-1 seroconversion",

abstract = "Primary infection with drug-resistant HIV-1 is well documented. We have followed up patients infected with such viruses to determine the stability of resistance-associated mutations. Fourteen patients who experienced primary infection with genotypic evidence of resistance were followed for up to 3 years. Drug resistance-associated mutations persisted over time in most patients studied. In particular, M41L, T69N, K103N, and T215 variants within reverse transcriptase (RT) and multidrug resistance demonstrated little reversion to wild-type virus. By contrast, Y181C and K219Q in RT, occurring alone, disappeared within 25 and 9 months, respectively. Multidrug resistance in 2 patients was found to be stable for up to 18 months, the maximum period studied. We conclude that certain resistance-associated mutations are highly stable and these data support the recommendation that all new HIV diagnoses in areas where primary resistance may occur should undergo genotyping irrespective of whether the date of seroconversion is known.",

keywords = "HIV-1, Persistence of mutations, Primary drug resistance",

author = "David Pao and Ushan Andrady and Janette Clarke and Gillian Dean and Susan Drake and Martin Fisher and Tanya Green and Siva Kumar and Maurice Murphy and Alan Tang and Stephen Taylor and David White and Gillian Underhill and Deenan Pillay and Patricia Cane",

year = "2004",

month = dec,

day = "15",

doi = "10.1097/00126334-200412150-00006",

language = "English",

volume = "37",

pages = "1570--1573",

journal = "Journal of Acquired Immune Deficiency Syndromes",

issn = "1525-4135",

publisher = "Lippincott, Williams & Wilkins",

number = "5",

}

Pao, D, Andrady, U, Clarke, J, Dean, G, Drake, S, Fisher, M, Green, T, Kumar, S, Murphy, M, Tang, A, Taylor, S, White, D, Underhill, G, Pillay, D & Cane, P 2004, 'Long-term persistence of primary genotypic resistance after HIV-1 seroconversion', Journal of Acquired Immune Deficiency Syndromes, vol. 37, no. 5, pp. 1570-1573. https://doi.org/10.1097/00126334-200412150-00006

TY - JOUR

T1 - Long-term persistence of primary genotypic resistance after HIV-1 seroconversion

AU - Pao, David

AU - Andrady, Ushan

AU - Clarke, Janette

AU - Dean, Gillian

AU - Drake, Susan

AU - Fisher, Martin

AU - Green, Tanya

AU - Kumar, Siva

AU - Murphy, Maurice

AU - Tang, Alan

AU - Taylor, Stephen

AU - White, David

AU - Underhill, Gillian

AU - Pillay, Deenan

AU - Cane, Patricia

PY - 2004/12/15

Y1 - 2004/12/15

N2 - Primary infection with drug-resistant HIV-1 is well documented. We have followed up patients infected with such viruses to determine the stability of resistance-associated mutations. Fourteen patients who experienced primary infection with genotypic evidence of resistance were followed for up to 3 years. Drug resistance-associated mutations persisted over time in most patients studied. In particular, M41L, T69N, K103N, and T215 variants within reverse transcriptase (RT) and multidrug resistance demonstrated little reversion to wild-type virus. By contrast, Y181C and K219Q in RT, occurring alone, disappeared within 25 and 9 months, respectively. Multidrug resistance in 2 patients was found to be stable for up to 18 months, the maximum period studied. We conclude that certain resistance-associated mutations are highly stable and these data support the recommendation that all new HIV diagnoses in areas where primary resistance may occur should undergo genotyping irrespective of whether the date of seroconversion is known.

AB - Primary infection with drug-resistant HIV-1 is well documented. We have followed up patients infected with such viruses to determine the stability of resistance-associated mutations. Fourteen patients who experienced primary infection with genotypic evidence of resistance were followed for up to 3 years. Drug resistance-associated mutations persisted over time in most patients studied. In particular, M41L, T69N, K103N, and T215 variants within reverse transcriptase (RT) and multidrug resistance demonstrated little reversion to wild-type virus. By contrast, Y181C and K219Q in RT, occurring alone, disappeared within 25 and 9 months, respectively. Multidrug resistance in 2 patients was found to be stable for up to 18 months, the maximum period studied. We conclude that certain resistance-associated mutations are highly stable and these data support the recommendation that all new HIV diagnoses in areas where primary resistance may occur should undergo genotyping irrespective of whether the date of seroconversion is known.

KW - HIV-1

KW - Persistence of mutations

KW - Primary drug resistance

UR - http://www.scopus.com/inward/record.url?scp=10644238065&partnerID=8YFLogxK

U2 - 10.1097/00126334-200412150-00006

DO - 10.1097/00126334-200412150-00006

M3 - Article

C2 - 15577410

AN - SCOPUS:10644238065

SN - 1525-4135

VL - 37

SP - 1570

EP - 1573

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

IS - 5

ER -

Long-term persistence of primary genotypic resistance after HIV-1 seroconversion

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this